According to the Centers for Disease Control (CDC), more than 24 million Americans live with diabetes. The disease can cause poor circulation in the limbs and puts diabetics at higher risk of developing CLI, or a lack of blood supply in the legs, which can lead to amputation. In fact, the risk of losing a foot or leg is 15-40 times higher for diabetics than for those without the disease, according to the American Diabetes Association (ADA). Revascularization technologies, such as JETSTREAM, can help restore blood flow and save the limbs of diabetic patients. However, not all devices are designed to treat small blood vessels found in the lower legs.

JETSTREAM G3 SF is the only below-the-knee device on the market that offers active aspiration, a feature that continually removes debris from the treatment site. JETSTREAM G3 SF is optimized for below-the-knee blockages and features a smaller, fixed cutter designed for enhanced performance in tortuousity (curves) and better navigation of the device through arteries of the lower leg.

"Our ongoing commitment to innovation has helped solidify Pathway's position as a leader in the PVD market," said Paul Buckman, president and CEO, Pathway Medical Technologies. "Through continual expansion and refinement of JETSTREAM, we are now able to reach and help a varied population of PAD sufferers with minimally invasive treatment options, helping them recover and return more quickly to normal, active lives."

SOURCE Pathway Medical Technologies, Inc.